Axsome Therapeutics Wins FDA Nod for Auvelity in Alzheimer’s Agitation, Launch Set for June

Key Points

• FDA approved Auvelity for agitation associated with dementia due to Alzheimer’s disease, expanding the drug’s indication beyond major depressive disorder, and Axsome plans a full commercial launch in June with about 630 sales reps targeting ~68,000 prescribers.
• Two supporting trials showed efficacy: ADVANCE‑1 produced a statistically significant improvement on the Cohen‑Mansfield Agitation Inventory by week 5, and ACCORD‑2 found continued Auvelity reduced relapse risk by about 72% versus placebo, indicating rapid and durable benefit.
• Axsome expects broad access—≈100% Medicare/Medicaid coverage and ~78% commercial coverage—with roughly 75% of agitation patients not requiring prior authorization; the label adds a hyponatremia caution but there is no new box warning and discontinuation rates matched placebo in trials.

Axsome Therapeutics NASDAQ: AXSM announced that the U.S. Food and Drug Administration has approved Auvelity for the treatment of agitation associated with dementia due to Alzheimer’s disease, expanding the product’s indications beyond major depressive disorder. The approval and the company’s commercialization plans were discussed on a conference call led by Chief Operating Officer Mark Jacobson, with remarks from CEO Dr. Herriot Tabuteau, Chief Commercial Officer Ari Maizel, CFO Nick Pizzie, and Alzheimer’s disease agitation expert Dr. Jeffrey Cummings of the UNLV Kirk Kerkorian School of Medicine.

FDA approval and clinical data highlighted

Dr. Tabuteau said the approval provides “an important new treatment option” for a condition where “treatment options have been limited.” He described Auvelity as “a first-in-class medicine with a distinct mechanism of action,” noting that Alzheimer’s disease agitation was the second indication for which Auvelity has received FDA Breakthrough Therapy designation, and that the application was granted Priority Review and approval.

In discussing how the drug works, Tabuteau said Auvelity targets mGluR and sigma-1 receptors that are believed to modulate neurotransmitter systems implicated in Alzheimer’s disease, while adding that “the exact mechanism of action of Auvelity in the treatment of agitation associated with dementia is unclear.” He also noted that with the new indication there is “no new box warning.”

Axsome presented results from two trials supporting the approval:

• ADVANCE-1 (5-week parallel-group study): Auvelity met the primary endpoint with a statistically significant improvement on the Cohen-Mansfield Agitation Inventory (CMAI) total score at week 5. Patients on Auvelity had a 14.9-point reduction versus an 11.6-point reduction on placebo. Tabuteau said separation versus placebo was numerically greater starting at week 2. A key secondary endpoint—clinician-rated improvement on a modified Alzheimer’s Disease Cooperative Study Clinical Global Impression of Change for agitation—also favored Auvelity.
• ACCORD-2 (long-term randomized withdrawal trial): Patients who continued Auvelity had a statistically significantly greater time to relapse versus those switched to placebo in an up to six-month double-blind phase. Tabuteau said Auvelity reduced the risk of re-relapse by 72% compared to placebo, with 28.6% of placebo patients relapsing versus 8.4% on Auvelity.

Tabuteau characterized the overall profile as “rapid and durable improvement” and said Auvelity was well-tolerated in trials with Alzheimer’s disease patients, with a discontinuation rate “identical to placebo.”

Market opportunity and launch planning

Maizel said agitation in Alzheimer’s disease dementia represents a significant unmet need, estimating that more than 5 million people in the U.S. have Alzheimer’s disease agitation and that the figure is projected to double in coming decades. He added that approximately half of patients are currently treated with pharmacotherapies, and noted that only one previously approved treatment reached the market in 2023.

Maizel described a treatment landscape split between community and long-term care settings. He said the majority of patients live in the community and generally have mild to moderate symptoms, while “nearly 4 out of 10” reside in long-term care facilities and generally have moderate to severe symptoms. Treatment decisions, he said, are “overwhelmingly made by primary care providers,” with psychiatrists, neurologists, and geriatric specialists also playing important roles.

Axsome’s launch plan includes an expanded sales team of about 630 representatives targeting roughly 68,000 healthcare professionals. Maizel said there is “substantial overlap” with Auvelity’s existing prescriber base in major depressive disorder, which the company expects to support adoption. He also said launch preparations should be completed in about one month, with a “full commercial launch planned in June.”

Payer coverage, utilization management, and financial commentary

On payer access, Maizel said coverage for Auvelity is “strong,” with approximately 100% of lives covered in Medicare and Medicaid, which he said represent nearly 90% of the expected payer mix in Alzheimer’s disease agitation. He added that approximately 78% of commercially insured lives have coverage.

In response to questions about utilization management, Maizel said Axsome has worked with payers and PBMs to extend access to the new indication and stated that “approximately 75% of agitation patients will not require prior authorization” once prescribed, describing that status as active going into launch.

CFO Nick Pizzie addressed gross-to-net expectations, saying the company anticipates gross-to-net for 2026 will look similar to 2025 and that the Alzheimer’s disease agitation approval is not expected to change the metric materially in the near term. He also reiterated the company’s longer-term view that gross-to-net would “likely level out in the 50s range.”

Physician and caregiver perspective on agitation and treatment needs

Dr. Cummings described agitation as encompassing excessive motor activity, verbal aggression, and physical aggression, citing the International Psychogeriatric Association definition. He said agitation can occur across disease severity and noted high prevalence in moderate to severe patients. He also reviewed the CMAI as the regulatory instrument used in trials.

He emphasized that agitation is “among the most prevalent and distressing” neuropsychiatric symptoms, associated with accelerated progression, functional decline, earlier institutionalization, and increased fall and mortality risk. He also outlined limitations of commonly used off-label treatments—such as sedation, extrapyramidal effects, falls, worsening cognition, and cardiovascular and cerebrovascular events—and highlighted that atypical antipsychotics carry a black box warning for increased mortality risk in elderly patients with dementia.

Discussing Auvelity’s positioning, Cummings said it is “not a PRN medication,” adding that patients tend to remain “agitation-prone” over a period of about three years and that compliance is generally high because caregivers administer treatment and are motivated by symptom burden. He also suggested Auvelity could be viewed as a first-line therapy for many patients, in part because a black box warning can discourage use of antipsychotics.

Label and safety discussion

During Q&A, the company noted an addition to the label related to hyponatremia, stating it was based on one case in the overall clinical development program and that the FDA wanted clinicians to be aware of hyponatremia risk in elderly populations. The company also said its clinical studies did not include concomitant dosing with other serotonergic antidepressants.

In closing remarks, Tabuteau said the approval “exemplifies our mission to deliver innovative new treatment options” and stated that Axsome now has three commercial products approved across four conditions, alongside a pipeline that includes six novel product candidates targeting 10 areas of unmet need.

About Axsome Therapeutics NASDAQ: AXSM

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome's pipeline includes several late-stage and approved product candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.